Avant Brands Inc. and IM Cannabis Corp. announced the signing of an international trademark licensing agreement (the "Licensing Agreement") granting IMC the exclusive right to launch the BLKMKT brand in the Israeli medical cannabis market. The Licensing Agreement constitutes a significant milestone in the maturing and mutually beneficial relationship between the two premium cannabis companies in the Canadian and Israeli medical cannabis markets.

Under the terms of the License Agreement, a subsidiary of Avant will license the Company's premium-cannabis BLKMKT brand to an Israeli subsidiary of IMC for use on IMC's medical cannabis product packaging. All such packaging will contain cannabis cultivated exclusively by Avant, and sold to IMC affiliates. The integration of unique and exclusive varieties of the high-quality BLKMKT brand into the current IMC premium product portfolio will serve to bolster the cooperative and synergistic partnership forged between the two companies over the past two years.

It will further strengthen IMC's business model in Israel that offers medical cannabis patients quality, ultra-premium brands, such as WAGNERS, IMC, and more. The Licensing Agreement signals IMC's commitment to implementing a premium strategy and acts as another step to establish the Company's leadership of the ultra-premium segment in Israel. IMC and Avant have enjoyed tremendous success from their partnership so far, which combines Avant's top-of-the-line products and IMC's excellent go-to-market execution.

Due to this growing partnership, ultra-premium-priced strains, such as Alien SinMint Cookies and Watermelon Zkittlez, sold out in record time. Avant has made multiple shipments to Israel under the terms of a previously announced supply agreement with Focus Medical Herbs Ltd. ("Focus Medical"). In order to facilitate these exports, Avant's cultivation facilities must successfully complete rigorous audits in order to secure ICANN-G.A.P accreditation from the Israeli Institute of Quality & Control.